US fast track for Shire’s liver drug
US regulators have placed Shire’s SHP626 on a fast-track regulatory pathway in the hope of potentially accelerating access to the experimental liver disease drug.
Read More
Tag: ASBT
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
